|
IL36670A
(en)
|
1971-04-21 |
1974-09-10 |
Sela M |
Therapeutic basic copolymers of amino acids
|
|
IL113812A
(en)
|
1994-05-24 |
2000-06-29 |
Yeda Res & Dev |
Copolymer-1 pharmaceutical compositions containing it and its use
|
|
IL119989A0
(en)
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
US6214791B1
(en)
|
1997-01-10 |
2001-04-10 |
Yeda Research And Development Co. Ltd. |
Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
|
|
JP2003521448A
(ja)
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
EP2090583B1
(en)
|
1998-09-25 |
2011-07-13 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
AU6281599A
(en)
|
1998-10-02 |
2000-04-26 |
Yeda Research And Development Co. Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
AU775073C
(en)
|
1998-11-12 |
2007-05-03 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
|
|
EP1248643B1
(en)
|
2000-01-20 |
2005-08-17 |
YEDA RESEARCH AND DEVELOPMENT Co. LTD. |
The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
|
|
JP2003522799A
(ja)
|
2000-02-18 |
2003-07-29 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス |
コポリマー１の経口、経鼻および経肺投与製剤
|
|
ZA200206457B
(en)
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
PL363431A1
(en)
|
2000-06-05 |
2004-11-15 |
Teva Pharmaceuticals Industries, Ltd. |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
DE60116467T2
(de)
|
2000-06-07 |
2006-11-02 |
Yeda Research And Development Co., Ltd. |
Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
CA2469393C
(en)
|
2001-12-04 |
2010-05-25 |
Teva Pharmaceutical Industries, Ltd. |
Processes for the measurement of the potency of glatiramer acetate
|
|
US7351686B2
(en)
|
2001-12-06 |
2008-04-01 |
Yeda Research And Development Co. Ltd. |
Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
|
|
US7507531B2
(en)
|
2002-10-17 |
2009-03-24 |
Decode Genetics Chf. |
Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
|
|
US7851486B2
(en)
|
2002-10-17 |
2010-12-14 |
Decode Genetics Ehf. |
Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
|
|
US20060019269A1
(en)
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
|
US20080293750A1
(en)
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
|
EP1565486A2
(en)
|
2002-11-13 |
2005-08-24 |
Apotex Pharmachem Inc. |
Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
|
|
WO2004060265A2
(en)
|
2003-01-07 |
2004-07-22 |
Yeda Research And Development Co. Ltd. |
Eye-drop vaccine containing copolymer 1 for therapeutic immunization
|
|
NZ569331A
(en)
|
2003-01-21 |
2010-08-27 |
Yeda Res & Dev |
COP 1 for treatment of inflammatory bowel diseases
|
|
EP1603530A1
(en)
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
HRP20140524T1
(hr)
|
2003-05-14 |
2014-12-19 |
Teva Pharmaceutical Industries Ltd. |
Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze
|
|
US20050064483A1
(en)
|
2003-08-28 |
2005-03-24 |
Baylor College Of Medicine |
Gene expression profiling technology for treatment evaluation of multiple sclerosis
|
|
CA2540701A1
(en)
|
2003-09-29 |
2005-04-07 |
Chugai Seiyaku Kabushiki Kaisha |
Proteins expressed in nk cells
|
|
US20050170004A1
(en)
|
2003-10-31 |
2005-08-04 |
Vered Rosenberger |
Nanoparticles for drug delivery
|
|
EP1684797A1
(en)
|
2003-11-12 |
2006-08-02 |
Yeda Research and Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
JP2007538003A
(ja)
|
2004-01-30 |
2007-12-27 |
デコード ジェネティクス イーエッチエフ． |
心筋梗塞、脳卒中および末梢動脈閉塞疾患に対する感受性遺伝子、治療の方法
|
|
US20100216863A1
(en)
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
|
US20050266432A1
(en)
*
|
2004-02-26 |
2005-12-01 |
Illumina, Inc. |
Haplotype markers for diagnosing susceptibility to immunological conditions
|
|
CA2558380A1
(en)
|
2004-03-03 |
2005-09-15 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and riluzole
|
|
US20050266410A1
(en)
|
2004-05-19 |
2005-12-01 |
Emily Walsh |
Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
|
|
US20060229233A1
(en)
|
2004-06-25 |
2006-10-12 |
Id Biomedical Corporation |
Compositions and methods for treating neurological disorders
|
|
CA2579038A1
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
NZ554018A
(en)
|
2004-09-09 |
2009-06-26 |
Teva Pharma |
Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
|
|
DK1797109T3
(en)
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
|
WO2006050122A1
(en)
|
2004-10-29 |
2006-05-11 |
Sandoz Ag |
Processes for preparing glatiramer
|
|
US20060172942A1
(en)
|
2005-02-02 |
2006-08-03 |
Teva Pharmaceutical Industries, Ltd. |
Process for producing polypeptide mixtures using hydrogenolysis
|
|
HRP20130622T1
(en)
|
2005-02-17 |
2013-08-31 |
Teva Pharmaceutical Industries Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
US20100167983A1
(en)
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
EP1891233A4
(en)
*
|
2005-04-25 |
2010-03-24 |
Yeda Res & Dev |
MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
|
|
WO2007030573A2
(en)
|
2005-09-09 |
2007-03-15 |
Yeda Research And Development Co. Ltd. |
Polypeptides useful for molecular weight determinations
|
|
US20070161566A1
(en)
*
|
2006-01-11 |
2007-07-12 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
ES2338488T3
(es)
|
2006-07-05 |
2010-05-07 |
Momenta Pharmaceuticals, Inc. |
Proceso mejorado para la preparacion de copolimero-1.
|
|
US20080131887A1
(en)
*
|
2006-11-30 |
2008-06-05 |
Stephan Dietrich A |
Genetic Analysis Systems and Methods
|
|
US7795033B2
(en)
|
2007-03-19 |
2010-09-14 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods to predict the outcome of treatment with antidepressant medication
|
|
CN101877963A
(zh)
|
2007-11-28 |
2010-11-03 |
泰华制药工业有限公司 |
延缓临床确诊的多发性硬化症发作的方法
|
|
US20090177487A1
(en)
|
2008-01-07 |
2009-07-09 |
Tera Eerkes |
Methods for Assessing Genetic Compatibility
|
|
WO2009150550A2
(en)
|
2008-06-13 |
2009-12-17 |
Prognomix, Inc. |
Genetic component of complications in type 2 diabetes
|
|
WO2010003016A2
(en)
|
2008-07-04 |
2010-01-07 |
Axial Biotech, Inc |
Genetic markers associated with degenerative disc disease and uses thereof
|
|
EP2406396A2
(en)
*
|
2009-03-12 |
2012-01-18 |
Brainco Biopharma, S.L. |
A genotyping tool for improving the prognostic and clinical management of ms patients
|
|
WO2010118210A1
(en)
|
2009-04-08 |
2010-10-14 |
Cedars-Sinai Medical Center |
Methods of predicting complication and surgery in crohn's disease
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
PL2275086T3
(pl)
|
2009-07-15 |
2012-09-28 |
Teva Pharma |
Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania
|
|
SG10201405806SA
(en)
|
2009-08-20 |
2014-11-27 |
Yeda Res & Dev |
Low Frequency Glatiramer Acetate Therapy
|
|
WO2011043823A2
(en)
|
2009-10-09 |
2011-04-14 |
Georgetown University |
Polypeptides that home to atherosclerotic plaque
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
ES2602977T3
(es)
|
2010-10-11 |
2017-02-23 |
Teva Pharmaceutical Industries Ltd. |
Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
|
|
AU2012323345A1
(en)
|
2011-10-10 |
2014-05-22 |
Teva Pharmaceutical Industries Ltd. |
Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
AU2013361053A1
(en)
|
2012-12-21 |
2015-07-30 |
Teva Pharmaceutical Industries Ltd. |
Transmucosal delivery of glatiramer acetate
|
|
KR20150111919A
(ko)
|
2012-12-21 |
2015-10-06 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트의 경구 경점막 전달
|
|
EP2941274A4
(en)
|
2013-01-04 |
2016-11-16 |
Teva Pharma |
CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE
|
|
TW201521757A
(zh)
|
2013-03-12 |
2015-06-16 |
Teva Pharma |
先後通過利妥昔單抗（ｒｉｔｕｘｉｍａｂ）誘導治療及格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）治療
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|